Effects of E prostaglandins on canine gastric potential difference
- PMID: 677095
- DOI: 10.1007/BF01072927
Effects of E prostaglandins on canine gastric potential difference
Abstract
Measurement of the gastric transmucosal potential difference (PD) was used to study the effect of gastric antisecretory prostaglandins on the integrity of the gastric mucosa of the Heidenhain pouch dog. Intragastric administration of SC-29333 [(+/-)-15-deoxy-16-alpha,beta-hydroxy-16-methyl PGE1 methyl ester] slightly but significantly increased the transmucosal PD when compared to vehicle control. In addition, SC-29333 administered either intravenously or intragastrically, significantly inhibited the PD fall induced by aspirin, a well-established barrier breaker. In contrast, the intragastric administration of 16,16-dimethyl PGE2 methyl ester (Me-PGE2) significantly lowered the transmucosal PD and failed to modify the actions of aspirin on the integrity of the gastric mucosa. However, the intravenous administration of either prostaglandin did not affect the basal transmucosal PD values. These studies suggest that SC-29333 may strengthen the integrity of the gastric mucosal barrier against aspirin, and this could have important therapeutic potential.
Similar articles
-
The cytoprotective effects of (+/-)-15-deoxy-16-alpha, beta-hydroxy-16-methyl PGE1 methyl ester (sc-29333) versus aspirin-shock gastric ulcerogenesis in the dog.Prostaglandins. 1981;21 Suppl:119-24. doi: 10.1016/0090-6980(81)90127-1. Prostaglandins. 1981. PMID: 6795683
-
Effect of topical 16,16-dimethyl prostaglandin E2 on aspirin-induced disruption of gastric permeability barrier in dogs.Prostaglandins. 1981;21 Suppl:125-9. doi: 10.1016/0090-6980(81)90128-3. Prostaglandins. 1981. PMID: 7302257
-
The effect of prostaglandin E2, 15-methyl prostaglandin E2, and metiamide on established canine gastric mucosal barrier damage.Surgery. 1979 Mar;85(3):333-8. Surgery. 1979. PMID: 425004
-
Gastric alkaline response to mucosa-damaging agents: effect of 16,16-dimethyl prostaglandin E2.Am J Physiol. 1981 Dec;241(6):G509-15. doi: 10.1152/ajpgi.1981.241.6.G509. Am J Physiol. 1981. PMID: 7325242
-
Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.Gastroenterology. 1976 Mar;70(3):359-70. Gastroenterology. 1976. PMID: 174967 Review.
Cited by
-
Healing of benign gastric ulcer. A placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1.Dig Dis Sci. 1985 Nov;30(11 Suppl):164S-170S. doi: 10.1007/BF01309404. Dig Dis Sci. 1985. PMID: 3932050 Clinical Trial.
-
Inhibitory effect of misoprostol on gastric acid secretion in vitro. Qualitative differences from natural prostaglandins.Dig Dis Sci. 1988 Oct;33(10):1265-8. doi: 10.1007/BF01536677. Dig Dis Sci. 1988. PMID: 3139378
-
Misoprostol versus antacid titration for preventing stress ulcers in postoperative surgical ICU patients.Ann Surg. 1989 Nov;210(5):590-5. doi: 10.1097/00000658-198911000-00004. Ann Surg. 1989. PMID: 2510618 Free PMC article. Clinical Trial.
-
Prostaglandin E1 (misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healing.Dig Dis Sci. 1986 Feb;31(2 Suppl):68S-74S. doi: 10.1007/BF01309326. Dig Dis Sci. 1986. PMID: 3080292 Clinical Trial.
-
Antiulcer drugs and gastric mucosal integrity. Effects of misoprostol, 16,16-dimethyl PGE2, and cimetidine on hemodynamics and metabolic rate in canine gastric mucosa.Dig Dis Sci. 1992 Jul;37(7):1029-38. doi: 10.1007/BF01300283. Dig Dis Sci. 1992. PMID: 1319887